The effect of miR-1226-3p on Breast Cancer

Mohamadzade, Zahra; Mohammad Soltani, Bahram; Mahjoobi, Foroozandeh; Hoseinpour, Parisa

The effect of miR-1226-3p on Breast Cancer

Document Type : Original Research

Authors

Zahra Mohamadzade ¹

bahram mohammad soltani ¹

foroozandeh mahjoobi ²

Parisa Hoseinpour ³

¹ Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran

² Clinical Genetics Department, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran.

³ Breast Cancer Research Center, Iranian Center for Breast Cancer (ICBC) Academic Center for Education, Culture and Research (ACECR). Tehran, Iran

Abstract

Breast cancer is the leading cause of cancer-related mortality among women worldwide. In Iran, breast cancer ranks first among cancers diagnosed in women comprising 24.4% of all malignancies. Currently, the large number of etiological factors and the complexity of breast cancer present challenge for prevention and treatment. Breast cancer tumorigenesis can be described as a multi-step process in which a normal cell undergoes malignant transformation to a fully developed tumor through accumulations of genetic and epigenetic changes, on the other hand, Several studies indicated the signaling pathways role in Breast cancer. EGFR gene has been shown to be overexpressed in breast cancer .Dimerization of EGFR/HER2 induces breast cancer progression via activation of PI3K/AKT signaling cascade

MicroRNAs are endogenous, small non-coding RNAs that regulate gene expression at the transcriptional and posttranscriptional level. MicroRNAs pair with partially complementary sites in the 3′untranslated regions (UTRs) of target mRNAs, leading to translational repression and/or mRNA degradation. They play important roles in several cellular processes, such as proliferation, differentiation, apoptosis, and development, by simultaneously controlling the expression level of hundreds of genes. Here we demonstrated the tumor suppression effect of miR-1226-3p in Breast cancer by targeting EGFR oncogene.

Keywords

Breast Cancer

miRNA

Signaling pathways

20.1001.1.23222115.1400.12.4.1.3

Subjects

Molecular biotechnology

1. Sellers, T. A. (1997). Genetic factors in the pathogenesis of breast cancer: their role and relative importance. The Journal of nutrition, 127(5), 929S-932S.
2. Kolstad, H. A. (2008). Nightshift work and risk of breast cancer and other cancers—a critical review of the epidemiologic evidence. Scandinavian journal of work, environment & health, 5-22.
3. Davies, L., & Welch, H. G. (2006). Increasing incidence of thyroid cancer in the United States, 1973-2002. Jama, 295(18), 2164-2167.
4. Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003). Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences, 100(7), 3983-3988.
5. Ronckers, C. M., Erdmann, C. A., & Land, C. E. (2004). Radiation and breast cancer: a review of current evidence. Breast Cancer Research, 7(1), 21.
6. Ingvarsson, S. (2003). Molecular genetics of breast cancer. International Journal of Human Genetics, 3(2), 69-78.
7. Baselga, J., & Swain, S. M. (2009). Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nature Reviews Cancer, 9(7), 463.
8. Pal, S. K., & Mortimer, J. (2009). Triple-negative breast cancer: novel therapies and new directions. Maturitas, 63(4), 269-274.
9. Carey, L. A., Rugo, H. S., Marcom, P. K., Irvin Jr, W., Ferraro, M., Burrows, E., ... & Winer, E. P. (2008). TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer. Journal of Clinical Oncology, 26(15_suppl), 1009-1009.
10. Cai, Y., Yu, X., Hu, S., & Yu, J. (2009). A brief review on the mechanisms of miRNA regulation. Genomics, proteomics & bioinformatics, 7(4), 147-154.
11. Farazi, T. A., Spitzer, J. I., Morozov, P., & Tuschl, T. (2011). miRNAs in human cancer. The Journal of pathology, 223(2), 102-115.
12. Manikandan, J., Aarthi, J. J., Kumar, S. D., & Pushparaj, P. N. (2008). Oncomirs: the potential role of non-coding microRNAs in understanding cancer. Bioinformation, 2(8), 330.
13. Wiggins, J. F., Ruffino, L., Kelnar, K., Omotola, M., Patrawala, L., Brown, D., & Bader, A. G. (2010). Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer research, 0008-5472.
14. Tao, Z., Shi, A., Lu, C., Song, T., Zhang, Z., & Zhao, J. (2015). Breast cancer: epidemiology and etiology. Cell biochemistry and biophysics, 72(2), 333-338.
15. Roskoski Jr, R. (2014). The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacological research, 79, 34-74.
16. Lemmon, M. A., & Schlessinger, J. (2010). Cell signaling by receptor tyrosine kinases. Cell, 141(7), 1117-1134.
17. Rimawi, M. F., Shetty, P. B., Weiss, H. L., Schiff, R., Osborne, C. K., Chamness, G. C., & Elledge, R. M. (2010). Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer: Interdisciplinary International Journal of the American Cancer Society, 116(5), 1234-1242.
18. Xu, B., Tao, T., Wang, Y., Fang, F., Huang, Y., Chen, S & Chen, M. (2016). hsa-miR-135a-1 inhibits prostate cancer cell growth and migration by targeting EGFR. Tumor Biology, 37(10), 14141-14151.
19. Pereira, D. M., Rodrigues, P. M., Borralho, P. M., & Rodrigues, C. M. (2013). Delivering the promise of miRNA cancer therapeutics. Drug discovery today, 18(5-6), 282-289.
20. Guo, J., Gong, G., & Zhang, B. (2018). miR-539 acts as a tumor suppressor by targeting epidermal growth factor receptor in breast cancer. Scientific reports, 8(1), 2073.
21. Jin, C., Rajabi, H., & Kufe, D. (2010). miR-1226 targets expression of the mucin 1 oncoprotein and induces cell death. International journal of oncology, 37(1), 61-69.